As BiOptix Inc shifts its focus from biotech instead to buying cryptocurrency and blockchain companies, in the Fall 2017 management announced name change Riot Blockchain Inc. Riot Blockchain Inc. was a first mover on the NASDAQ as a pure play focused on blockchain technology. Management indicate intent to gain exposure to the blockchain ecosystem through targeted investments in the sector, with a primary focus on the bitcoin and Ethereum blockchains. The rollout of this strategy has commenced with a strategic investment in Coinsquare, a leading Canadian digital currency exchange Coinsquare.io The Company continues to maintain its existing (SBIR involved business) Bioptix business line and its royalty license stemming from an Exclusive License Agreement with Ceva Santé Animale S.A. ("Licensee").Formerly known as Venaxis Inc., and before that, AspenBio Pharma, the company had developed a blood test to detect a protein associated with inflammation of the appendix, but received a negative response from the FDA in 2014. The firm also owns intellectual property rights related to veterinary products BiOptix Inc.had been an analytical instrumentation company, develops an array-based bio molecule detection systems and molecular interaction analysis instruments. The companys products pipeline includes cell array biodetector systems, and biochip and optical cartridges; and pre-production small footprint and single cell biodetector systems. Its products are used to detect various molecules and micro organisms, including micro RNA, nucleic acids, proteins and antibodies, bacteria, viruses, carbohydrates, lipids, and low molecular weight drugs. The company serves clinical biomarkers and diagnostics, personalized medicine, infectious disease, drug discovery, biopharma and low molecular drug development, pharmaceutical research, biological warfare agents, academic research, environmental monitoring, kinetic analyses, forensics, antibody development, and quality control and process analysis industries.
